Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Shareholders Approve US IPO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A majority of Osmetech's shareholders have approved the firm's plans to proceed with an initial public offering and other proposals, according to a notice posted on the London Stock Exchange.

Last month, Osmetech said that it had filed with the US Securities and Exchange Commission for the IPO under the name of its newly proposed parent, GenMark Diagnostics.

At the time, the maker of microarray-based molecular diagnostics said that its board of directors had approved the proposal, which includes reorganizing the firm so that it becomes a wholly-owned subsidiary of GenMark, based in Pasdadena, Calif. They also approved moving its shares from the AIM, on which it currently trades, to the Nasdaq Global Market, under which shareholders would receive one share of GenMark for every 230 shares of Osmetech held.

According to the notice posted on the LSE today, Osmetech's shareholders approved the plans, with only 21 percent of shareholders representing .03 percent of Osmetech's shares voting against the proposals.

A court hearing is scheduled to take place on May 20 to sanction the plans.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.